Abstract: The use of a composition comprising a compound: where R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group for the preparation of a medicament or a pharmaceutical for the treatment of inflammatory diseases.

Abstract: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by ?-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.

Abstract: The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.

Abstract: Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

Abstract: An application development server for aid in developing software and a system, method, and apparatus for updating continuously the working definitions of an encapsulated application such that different views of a construct may be supported and that changes made in one view of the construct may be reflected in the other views of the construct. In a preferred embodiment of the application development server, the application server includes a processor, a memory unit, a storage unit, and a communications link to a network. The working definition defined environment is stored on the storage unit. The processor executes instructions stored in the memory unit that allow the application development server to receive requests for working definition defined environments from clients, retrieve the working definition defined environment from the storage unit and send the working definition defined environment to the client via the communications link to the network.

Abstract: A pharmaceutical composition that includes a peptide of formula Y-(X-aa)-Z. (X-aa) is generally an amino acid sequence selected from -Arg-Val-Ser-Val-Arg-Trp-, -Arg-Val-Ala-Val-Ile-, -His-Gly-Arg-Leu-Val-Phe-, -Leu-Ala-Phe-Val-Leu-Arg-, and -Thr-Leu-Phe-Leu-Ala-Arg-. And Y is generally an amino terminal modifying group selected from an amino acid, a N-acylated amino acid, a peptide, a N-acylated peptide, and hydrogen. And Z- is carboxyl-terminal modifying group selected from hydrogen, an amino acid, a C-amidated amino acid, a peptide, a C-amidated peptide, or an amide or hydroxyl group such as an alkyl amide, an aryl amide, or an alcohol. A composition of matter that includes at least one of the peptide sequences -Arg-Val-Ala-Val-Ile-, -Leu-Ala-Phe-Val-Leu-Arg-, -Thr-Leu-Phe-Leu-Ala-Arg-, -Arg-Val-Ser-Val-Arg-Trp-, -His-Gly-Arg-Leu-Val-Phe-. Preferably at least one amino acid of the peptide sequence is a D-amino acid.

Abstract: A pharmaceutical agent for treating an amyloid disease such as Alzheimer's Disease that includes a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genus Uncaria, species tomentosa, wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.

Abstract: A pharmaceutical composition comprising peptide A4G82 Thr-Leu-Phe-Leu-Ala-His-Gly-Arg- (SEQ ID NO: 11) Leu-Val-Phe-Met.

Abstract: A pharmaceutical composition comprising peptide A-13 Arg-Gln-Val-Phe-Gln-Val-Ala-Tyr-Ile-Ile-Ile-Lys-Ala (SEQ ID NO:3).

Abstract: A pharmaceutical composition comprising peptide AG73 Arg-Lys-Arg-Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg-Thr (SEQ ID NO:1).

Abstract: A pharmaceutical composition comprising peptide A5G81 Ala-Gly-Gln-Trp-His-Arg-Val-Ser- (SEQ ID NO: 15) Val-Arg-Trp-Gly.

Abstract: A pharmaceutical composition comprising peptide HA3G76 Tyr-Leu-Ser-Lys-Gly-Arg-Leu-Val-Phe-Ala-Leu-Gly (SEQ ID NO:8).

Abstract: A method, system, and apparatus for detecting and repairing damaged portions of a computer system is provided. In a preferred embodiment of the present invention, a damage detection and repair facility monitors and detects changes to the computer system. The damage detection and repair facility compares these changes to the set of constraints defined by the working definitions for each application installed on the computer system. The working definitions define the invariant portions of each application and define the constraints placed upon the computer system by each application. Responsive to changes that are in conflict with this set of constraints, the damage detection and repair facility makes such changes in the persistent storage so as to resolve these conflicts. This may be done, for example, by repairing a damaged file, installing a missing driver, or adjusting an environment variable.

Abstract: The invention relates to MR contrast media containing composite nanoparticles, preferably comprising a superparamagnetic iron oxide core provided with a coating comprising an oxidatively cleaved starch coating optionally together with a functionalized polyalkyleneoxide which serves to prolong blood residence.